Philippe Calais

Philippe P.
Calais is the founder of Phileas Pharma, Inc., founded in 2019, serving as Chairman.
Current jobs include President, Chief Executive Officer & Director at MatriSys Bioscience, Inc.; Executive Chairman & Chief Executive Officer at TransCode Therapeutics, Inc. since 2025; and Professor at Florida Atlantic University since 2019.
Former jobs include President, Chief Executive Officer & Director at Ambrilia Biopharma, Inc. (2008–2009); President & Chief Executive Officer at Univalor, Inc. (2011–2012); President & Chief Executive Officer at Isarna Therapeutics BV (2012–2018); Chairman at Neurochem (International) Ltd. (2003–2007); Director at CohBar, Inc. (2019–2020); Lead Independent Director at Adhera Therapeutics, Inc. (2017–2018); Director at Medpharmgene, Inc. (2011–2012); Director at Autotelic, Inc. (2016–2018); Director at Cite Des Biotechs De Laval (2002–2012); Director at Cognisense (2010–2012); President-Global Business at BELLUS Health, Inc. (2003–2007); Head-Global Strategic Marketing Unit at Hoffmann-La Roche, Inc.; and General Manager at Servier Canada, Inc. (2000–2002).
Education includes undergraduate studies at Université Pierre et Marie Curie and both undergraduate and doctorate degrees from Université François-Rabelais de Tours.